The use of protocrotaline in the preparation of anti-asthma medicine
What is Al technical title?
Al technical title is built by PatSnap Al team. It summarizes the technical point description of the patent document.
A technology of protomonetine and asthma, applied in the field of protomonitorine in the preparation of anti-asthma drugs
Active Publication Date: 2019-10-08
SHANGHAI JIAOTONG UNIV
View PDF3 Cites 0 Cited by
Summary
Abstract
Description
Claims
Application Information
AI Technical Summary
This helps you quickly interpret patents by identifying the three key elements:
Problems solved by technology
Method used
Benefits of technology
Problems solved by technology
At present, there are few reports on the activity of the monomeric component of protomonetine
Method used
the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more
Image
Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
Click on the blue label to locate the original text in one second.
Reading with bidirectional positioning of images and text.
Smart Image
Examples
Experimental program
Comparison scheme
Effect test
Embodiment 1
[0023] The structural formula of the compound protobadenine used in the present invention is as follows:
[0024]
[0025] Among the present invention, the mixture preparation method of DRA and aluminum agent is as follows:
[0026] Preparation of the DRA mix :D (m) :R (m) : A (m) =1:10:1, dissolved in PBS, the concentration is 6mg / ml, mixed with the aluminum agent at a volume ratio of 1:19, and mixed on a suspension apparatus at 4°C for 4-5 hours to obtain DRA and aluminum agent mixture.
[0027] DRA mixture formulation for intranasal administration: D (m) :R (m) : A (m) =1:10:1, dissolved in PBS, the concentration is 2mg / ml.
[0028] In the present example, through animal experiments, it was found that protobarkine has a significant therapeutic effect on asthma, and the experimental methods and results are as follows:
[0029] 1 Experimental materials
[0030] 1.1 Experimental animals:
[0031] C57 / BL mice, male, weighing 20-25 g, were purchased from the Experim...
Embodiment 2
[0057] Preparation of tablets:
[0058] Take 300g of protomonetine, add appropriate amount of starch to make granules, add appropriate amount of magnesium stearate, mix well, press into 1000 tablets for oral administration, 2 times a day, 2 tablets each time.
Embodiment 3
[0060] Preparation of capsules:
[0061] Take 300g of protomonetine, add appropriate amount of diluent, mix well, divide into empty capsules and get final product. Make 1000 capsules, 2 times a day, 2 capsules each time.
the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more
PUM
Login to view more
Abstract
The invention discloses application of protostemonine in preparing an anti-asthma medicine. Asthma is DRA (Dust mite, Ragweed, Aspergillus) induced asthma or Th2 mediated asthma. The invention discloses that a main active component of radix stemonae, namely protostemonine, has a remarkable inhibition function on asthma for a first time. Test shows that the protostemonine has important values in clinical treatment on asthma, and a novel direction is provided for research of anti-asthma medicines.
Description
technical field [0001] The invention relates to the technical field of drug development and application and the field of drug therapeutics, in particular to the use of protomonetine in the preparation of anti-asthma drugs. Background technique [0002] Asthma is a chronic inflammatory disease of the airway, a complex inflammatory pathological process involving lymphocytes, dendritic cells, macrophages, mast cells, eosinophils, basophils and epithelial cells in the immune system. Under the action of allergens (allergens), patients experience airway hyperresponsive changes such as increased bronchial reactivity, increased mucus production, airway wall remodeling, and airway lumen narrowing, resulting in short-term dyspnea and wheezing and chest pressure. Asthma is a highly prevalent disease in today's society, with 1 in 10 children or 12 adults suffering from asthma. Worldwide, there are more than 300 million people with asthma, and in the United States alone, the total cost...
Claims
the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more
Application Information
Patent Timeline
Application Date:The date an application was filed.
Publication Date:The date a patent or application was officially published.
First Publication Date:The earliest publication date of a patent with the same application number.
Issue Date:Publication date of the patent grant document.
PCT Entry Date:The Entry date of PCT National Phase.
Estimated Expiry Date:The statutory expiry date of a patent right according to the Patent Law, and it is the longest term of protection that the patent right can achieve without the termination of the patent right due to other reasons(Term extension factor has been taken into account ).
Invalid Date:Actual expiry date is based on effective date or publication date of legal transaction data of invalid patent.
Login to view more 
Login to view more